Materialise reports Q2 EPS EUR0.0 vs. EUR0.07 last year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 24 2025
0mins
Should l Buy MTLS?
Q2 Revenue Performance: Materialise reported a Q2 revenue of EUR 64.83 million, down from EUR 68.8 million the previous year, with growth in the Medical segment but declines in Manufacturing and Software due to geopolitical and economic challenges.
Operational Profitability Improvement: Despite revenue pressures and unfavorable exchange rate impacts, the company improved operational profitability through cost control measures and achieved a positive net result for the quarter.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MTLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MTLS
About MTLS
Materialise NV is a Belgium-based company that is engaged in the software industry. The Company is a provider of software and three-dimensional (3D) printing services that incorporates 3D printing experience into a wide range of software solutions and 3D printing services. It transforms businesses with three elements of align: quality, reliability, and repeatability through which it forms the backbone of the 3D printing industry. The solutions are built 3D printing applications in several industries, including healthcare, automotive, aerospace, art and design, and consumer goods. It also operates in the domestic market and worldwide, including Colombia, Brazil, Australia, Malaysia, China, Japan, Austria, Poland, Germany, and France, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Materialise NV Q4 2025 Earnings Call Highlights
- Dual Listing Advantage: Materialise NV completed its dual listing on Euronext Brussels, which, while not raising capital, broadens its European investor base and enhances operational flexibility, potentially paving the way for future ADS or share buyback initiatives.
- Share Buyback Implementation: The company announced a share buyback program of up to EUR 30 million, having already repurchased 187,500 shares for nearly USD 1 million, demonstrating a commitment to shareholder value and market confidence.
- Medical Business Growth: The Medical segment treated over 17,000 patients in 2025, surpassing a cumulative total of 700,000 patients, with expectations for continued double-digit growth, solidifying its position as a key growth driver for the company.
- Strong Financial Performance: In Q4 2025, revenue grew by 6.8% year-on-year to EUR 70.2 million, with a gross profit margin of 58.1% and adjusted EBIT of EUR 4 million, reflecting ongoing improvements in cost control and profitability.
See More
Materialise Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Materialise reported a GAAP EPS of $0.12 for Q4 2025, with revenue of $82.44 million exceeding expectations by $0.42 million and reflecting a year-over-year growth of 6.8%, indicating robust market performance.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q4 increased significantly to 9,524 kEUR from 4,306 kEUR in 2024, showcasing a marked improvement in profitability and reflecting enhanced operational efficiency.
- Free Cash Flow Performance: The free cash flow for Q4 2025 was 4,511 kEUR, down from 6,218 kEUR in 2024, yet still demonstrating solid cash flow management that supports future investments.
- Future Outlook: The company anticipates full-year revenues for 2026 to grow to a range of 273,000 to 283,000 kEUR, with continued investments in its Medical and Software segments while maintaining cost discipline, projecting adjusted EBIT of 10,000 to 12,000 kEUR, indicating strong growth potential.
See More
Materialise NV Reports Strong Q4 and Full Year 2025 Financial Results
- Significant Revenue Growth: Total revenue for Q4 2025 reached €70.164 million, a 6.8% increase year-over-year, demonstrating strong performance in the medical device sector, particularly with a 16.3% rise in medical segment revenue to €37.016 million, further solidifying market leadership.
- Improved Profitability: Adjusted EBITDA for Q4 2025 surged to €9.524 million from €4.306 million in the same period of 2024, reflecting successful cost control and operational efficiency, which is expected to enhance investor confidence.
- Robust Cash Flow: As of December 31, 2025, the company reported €133.918 million in cash and cash equivalents, with a net cash position improving to €70.805 million, indicating strong financial health and the ability to continue investing in R&D and market expansion.
- Optimistic Future Outlook: The company anticipates full-year revenues for 2026 to range between €273,000 and €283,000, with continued strong growth in the medical segment and a transition to a cloud-based subscription model in the software segment, showcasing proactive positioning for future market opportunities.
See More
Materialise NV Reports Strong Q4 and Full Year 2025 Financial Results
- Q4 Revenue Growth: Total revenue for Q4 2025 reached €70,164k, a 6.8% increase year-over-year, with the Medical segment growing 16.3% to €37,016k, highlighting strong demand in the healthcare market and reinforcing the company's leadership in 3D-printed medical devices.
- Gross Margin Improvement: The gross margin for Q4 2025 rose to 58.1%, up from 55.4% in Q4 2024, reflecting successful cost control and operational efficiency, which enhances overall profitability.
- Significant Net Profit Increase: Net profit for Q4 2025 was €6,206k, a substantial rise from €2,907k in Q4 2024, indicating a marked improvement in profitability and market performance, boosting investor confidence.
- Strong Cash Reserves: As of December 31, 2025, the company reported cash and cash equivalents of €133,918k, significantly up from €102,304k in 2024, demonstrating a robust financial position that provides ample funding for future investments and innovation.
See More
Materialise to Announce Q4 Earnings on February 19
- Earnings Announcement: Materialise is set to release its Q4 earnings on February 19 before the market opens, with expectations that the results will significantly impact stock price movements.
- Earnings Expectations: The consensus EPS estimate stands at $0.07, and achieving this target would positively reflect the company's profitability and bolster market confidence in its growth trajectory.
- Revenue Forecast: Analysts estimate revenue at $82.02 million, and meeting this expectation could enhance Materialise's competitive position in the industry while attracting increased investor interest.
- Historical Performance Review: Over the past year, Materialise has exceeded EPS estimates 50% of the time and revenue estimates 75% of the time, indicating a stable performance and growth potential in the market.
See More
Materialise Schedules Q4 2025 Financial Results Release
- Earnings Release Schedule: Materialise NV will release its financial results for Q4 2025 on February 19, 2026, at 2:30 a.m. ET, reflecting the company's ongoing commitment to transparency and investor communication.
- Management Conference Call: Senior management will hold a conference call on the same day at 8:30 a.m. ET to discuss the financial results, aiming to enhance investor confidence through direct communication and provide deeper financial insights.
- Webcast Access: Investors can access the live audio webcast of the conference call through the company's website, ensuring that all stakeholders can obtain key information in real-time, thereby improving information accessibility and transparency.
- Industry Leadership: As a global leader in 3D-printed medical devices and software, Materialise's financial results will provide critical data supporting its ongoing innovation and market leadership across multiple sectors, including healthcare, automotive, and aerospace.
See More
Materialise NV Q4 2025 Earnings Call Highlights
- Dual Listing Advantage: Materialise NV completed its dual listing on Euronext Brussels, which, while not raising capital, broadens its European investor base and enhances operational flexibility, potentially paving the way for future ADS or share buyback initiatives.
- Share Buyback Implementation: The company announced a share buyback program of up to EUR 30 million, having already repurchased 187,500 shares for nearly USD 1 million, demonstrating a commitment to shareholder value and market confidence.
- Medical Business Growth: The Medical segment treated over 17,000 patients in 2025, surpassing a cumulative total of 700,000 patients, with expectations for continued double-digit growth, solidifying its position as a key growth driver for the company.
- Strong Financial Performance: In Q4 2025, revenue grew by 6.8% year-on-year to EUR 70.2 million, with a gross profit margin of 58.1% and adjusted EBIT of EUR 4 million, reflecting ongoing improvements in cost control and profitability.
See More
Materialise Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Materialise reported a GAAP EPS of $0.12 for Q4 2025, with revenue of $82.44 million exceeding expectations by $0.42 million and reflecting a year-over-year growth of 6.8%, indicating robust market performance.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q4 increased significantly to 9,524 kEUR from 4,306 kEUR in 2024, showcasing a marked improvement in profitability and reflecting enhanced operational efficiency.
- Free Cash Flow Performance: The free cash flow for Q4 2025 was 4,511 kEUR, down from 6,218 kEUR in 2024, yet still demonstrating solid cash flow management that supports future investments.
- Future Outlook: The company anticipates full-year revenues for 2026 to grow to a range of 273,000 to 283,000 kEUR, with continued investments in its Medical and Software segments while maintaining cost discipline, projecting adjusted EBIT of 10,000 to 12,000 kEUR, indicating strong growth potential.
See More
Materialise NV Reports Strong Q4 and Full Year 2025 Financial Results
- Significant Revenue Growth: Total revenue for Q4 2025 reached €70.164 million, a 6.8% increase year-over-year, demonstrating strong performance in the medical device sector, particularly with a 16.3% rise in medical segment revenue to €37.016 million, further solidifying market leadership.
- Improved Profitability: Adjusted EBITDA for Q4 2025 surged to €9.524 million from €4.306 million in the same period of 2024, reflecting successful cost control and operational efficiency, which is expected to enhance investor confidence.
- Robust Cash Flow: As of December 31, 2025, the company reported €133.918 million in cash and cash equivalents, with a net cash position improving to €70.805 million, indicating strong financial health and the ability to continue investing in R&D and market expansion.
- Optimistic Future Outlook: The company anticipates full-year revenues for 2026 to range between €273,000 and €283,000, with continued strong growth in the medical segment and a transition to a cloud-based subscription model in the software segment, showcasing proactive positioning for future market opportunities.
See More
Materialise NV Reports Strong Q4 and Full Year 2025 Financial Results
- Q4 Revenue Growth: Total revenue for Q4 2025 reached €70,164k, a 6.8% increase year-over-year, with the Medical segment growing 16.3% to €37,016k, highlighting strong demand in the healthcare market and reinforcing the company's leadership in 3D-printed medical devices.
- Gross Margin Improvement: The gross margin for Q4 2025 rose to 58.1%, up from 55.4% in Q4 2024, reflecting successful cost control and operational efficiency, which enhances overall profitability.
- Significant Net Profit Increase: Net profit for Q4 2025 was €6,206k, a substantial rise from €2,907k in Q4 2024, indicating a marked improvement in profitability and market performance, boosting investor confidence.
- Strong Cash Reserves: As of December 31, 2025, the company reported cash and cash equivalents of €133,918k, significantly up from €102,304k in 2024, demonstrating a robust financial position that provides ample funding for future investments and innovation.
See More
Materialise to Announce Q4 Earnings on February 19
- Earnings Announcement: Materialise is set to release its Q4 earnings on February 19 before the market opens, with expectations that the results will significantly impact stock price movements.
- Earnings Expectations: The consensus EPS estimate stands at $0.07, and achieving this target would positively reflect the company's profitability and bolster market confidence in its growth trajectory.
- Revenue Forecast: Analysts estimate revenue at $82.02 million, and meeting this expectation could enhance Materialise's competitive position in the industry while attracting increased investor interest.
- Historical Performance Review: Over the past year, Materialise has exceeded EPS estimates 50% of the time and revenue estimates 75% of the time, indicating a stable performance and growth potential in the market.
See More
Materialise Schedules Q4 2025 Financial Results Release
- Earnings Release Schedule: Materialise NV will release its financial results for Q4 2025 on February 19, 2026, at 2:30 a.m. ET, reflecting the company's ongoing commitment to transparency and investor communication.
- Management Conference Call: Senior management will hold a conference call on the same day at 8:30 a.m. ET to discuss the financial results, aiming to enhance investor confidence through direct communication and provide deeper financial insights.
- Webcast Access: Investors can access the live audio webcast of the conference call through the company's website, ensuring that all stakeholders can obtain key information in real-time, thereby improving information accessibility and transparency.
- Industry Leadership: As a global leader in 3D-printed medical devices and software, Materialise's financial results will provide critical data supporting its ongoing innovation and market leadership across multiple sectors, including healthcare, automotive, and aerospace.
See More
